Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Euroz Hartleys Healthcare Conference 2022
17 slides from Botanix Pharmaceuticals's conference presentation, Jul 27, 2022
Slide 1: Euroz Hartleys Healthcare Conference Presentation - Key highlights
27 July 2022 Euroz Hartleys Healthcare Conference Presentation Key highlights For personal use only • Release of updated corporate presentation to be delivered at Euroz Hartleys Healthcare Conference being held today in Perth including a number of other leading ASX listed companies • The presentatio
Slide 2: About Botanix and Cautionary Note on Forward-Looking Statements
antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Botanix leverages its proprietary drug delivery system (PermetrexTM) for direct skin delivery of active pharmaceuticals in all skin diseases, which is utilised in its exi
Slide 3: Euroz Hartleys Healthcare Conference July 2022
Euroz Hartleys For personal use only Healthcare Conference July 2022 Preparing to file first dermatology product for FDA approval in Q3 2022 1
Slide 4: Botanix: a leader in topical dermatology drug development
Pharmaceutical focus New treatments for common skin diseases - such as excessive sweating (hyperhidrosis), rosacea and acne For personal use only Topically driven Targeting key indications with topical treatments that are safe, well tolerated and validated with clinical efficacy Botanix: a leader in
Slide 5: Corporate Overview
Corporate Positioned to transition to Overview commercial dermatology company For personal use only ASX: BOT TRADING INFORMATION Share price A$0.081 6-month low / high A$0.052/0.095 SHARE PRICE PERFORMANCE Shares outstanding 979,233,384 Market Capitalisation A$79.3m Cash (31 Mar 2022) A$ 16.4m Debt
Slide 6: Sofpironium Bromide leads late-stage pipeline
Sofpironium Bromide leads late-stage pipeline Planned for FDA filing in 3Q 2022 with 12-month review period For personal use only INDICATION PRODUCT PHASE 1 PHASE 1B PHASE 2 PHASE 3 APPROVED STATUS (CY) Axillary Hyperhidrosis Sofprionium (excessive underarm FDA approval filing Bromide sweating) plan
Slide 7: Sofpironium Bromide
For personal use only Bromide Sofpironium
Slide 8: Accelerating Botanix towards revenue generation
Addressing unmet needs Accelerating First and only new chemical entity for “primary axillary Botanix towards hyperhidrosis” For personal use only revenue generation Positive Phase 3 Data All co-primary and secondary endpoints were statistically significant and side effects were mild to moderate with
Slide 9: Hyperhidrosis
Hyperhidrosis A medical condition where excessive For personal use only sweating occurs beyond what is needed to maintain normal body temperature Hyperhidrosis affects ~16M people in the US1: • Results from overstimulation of the nervous system (a physiological not psychological condition)1 • 90% of
Slide 10: Sofpironium Bromide mechanism of action
Sofpironium Bromide mechanism of action Blocks sweat gland receptors and rapidly degrades for excretion For personal use only 8
Slide 11: Phase 3 co-primary endpoints highly statistically significant
Phase 3 co-primary Measured reduction in Gravimetric endpoints - highly Sweat Production (GSP) and statistically significant HDSM-Ax-7 scale responses For personal use only Pooled Data (Cardigan I and II) Pooled Data (Cardigan I and II) ≥2-point improvement in HDSM-Ax-7 GSP change from baseline to f
Slide 12: Secondary efficacy endpoint: HDSM-Ax-7 reduction
Pooled Data (Cardigan I and II) HDSM-Ax-7 reduction (≥1-point improvement) from baseline to end of treatment1 For personal use only 100% p=0.0002 80% 84.6% 72.3% 60% Responders Secondary 40% Efficacy % Endpoint: 20% Almost 85% of patients 0% Vehicle SB 15% experienced a statistically (n=325) (n=319)
Slide 13: Hyperhidrosis treatment continuum
Hyperhidrosis No new chemical entities have been treatment continuum approved for hyperhidrosis For personal use only OLDER PRESCRIPTION ANTIPERSPIRANTS INVASIVE PROCEDURES SURGERY PRODUCTS OTC Aluminum Botox Cutting Chloride injection Nerves Reformulated Heat energy Clinical oral drug into device S
Slide 14: Significant opportunity for a new topical agent
Significant opportunity for a new topical agent with class leading efficacy and safety For personal use only OLDER PRESCRIPTION ANTIPERSPIRANTS NEW CHEMICAL ENTITIES INVASIVE PROCEDURES SURGERY PRODUCTS Aluminum Botox Cutting OTC Chloride injection Nerves Sofpironium Clinical Bromide Reformulated or
Slide 15: Market opportunity for hyperhidrosis
Market opportunity for Even a modest market share provides a hyperhidrosis1 significant financial opportunity For personal use only 336,107m USA population Share of patients already Patients Potential gross seeking treatment sales* 16.1m Hyperhidrosis patients 0.5% 18,500 $144,300,000 11.2m 1.0% 36,
Slide 16: Executing on key commercial and clinical milestones
Executing on key commercial and clinical milestones For personal use only Calendar year Sofpironium Rosacea Dermatitis Antimicrobial Acne Bromide BTX 1702 BTX 1204A BTX 1801 BTX 1503 FDA filing for Enrolment Enrolment Phase 2 study Study start pending approval in complete, complete, preparing to com
Slide 17: Important Notice & Disclaimer
Important Notice & Disclaimer 1. Summary information This presentation has been prepared by Botanix Pharmaceuticals Ltd (“Botanix”) and contains summary information about Botanix and the business conducted by it which is current as at the date of this presentation (“Presentation”) (unless otherwise
Botanix Pharmaceuticals — Euroz Hartleys Healthcare Conference 2022 on 6ix